Clinical Trial

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

Study acronym: PSSIT
Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-10-15; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2022-06-24
Trial Details
NCT Number NCT05098704
Lead Sponsor University Hospital, Bordeaux
Collaborators: Ministry for Health and Solidarity, France
Conditions Scleroderma, Systemic Sclerosis
Enrollment 90 participants
Start Date 2022-06-22
Primary Completion 2032-06 (estimated)
Study Completion 2032-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-07